Payment overview · 2025
General Payments
$4,425.49
101 reported records · 19 companies
Healthcare provider profile · identity verified
Kruten M Patel, DO
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ALBANY, IN · NPI 1801358031
Verified facts
What the public records show
CMS Open Payments records show Kruten M Patel, DO received $4,425.49 in general payments during 2025 across 101 reported records.
ABIOMED accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $1,428.85 | 32.3% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $714.57 | 16.1% | 25 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $689.82 | 15.6% | 31 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$528.84 | 11.9% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $182.73 | 4.1% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $147.35 | 3.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $140.75 | 3.2% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $124.55 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.01 | 2.2% | 6 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $75.13 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.30 | 1.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.53 | 1.2% | 3 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $40.40 | 0.9% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $34.38 | 0.8% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $22.81 | 0.5% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $22.11 | 0.5% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $22.06 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.02 | 0.3% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $14.28 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,241.87 | 95 |
| Travel and Lodging | $925.74 | 4 |
| Education | $257.88 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $689.82 | 31 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $321.06 | 6 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $214.02 | 10 | 2025 |
Source payment records
|
|||||
| RESOLUTE ONYX Normalized: resolute onyx |
Device | Medtronic, Inc. | $182.75 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $147.35 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $147.35 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $137.07 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $124.55 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $103.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.01 | 6 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $97.74 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $93.38 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $89.04 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $75.13 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $61.39 | 4 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $57.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.53 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $52.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $43.01 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| VASCBAND Normalized: vascband |
Device | Teleflex LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $21.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 33 | 19 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,425.49 · 101 records | ABIOMED | ABRE, ACCOLADE SR, ASSURITY, AURORA EV-ICD MRI SURESCAN, AVEIR, Adempas, Assure WCD, CARDIOMEMS, CT THROMBECTOMY SYSTEM KIT, Coronary Other, DIAMONDBACK CORONARY, DIAMONDBACK PERIPHERAL, EMBLEM MRI S-ICD, ESPRIT, FARXIGA, FLOWTRIEVER CATHETER, S, HAWKONE, IGT Devices Undivided, Indigo System, KENGREAL, Kerendia, LEQVIO, Labosys, Ozempic, PERCLOSE PROSTYLE, R2P MISAGO, RESOLUTE ONYX, SAVVYWIRE, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Tyvaso, VASCBAND, VITALPATCH RTM, Wegovy | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error